Moors & Cabot Inc. Invests $429,000 in Mylan N.V. (MYL)

Moors & Cabot Inc. acquired a new stake in shares of Mylan N.V. (NASDAQ:MYL) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 11,075 shares of the company’s stock, valued at approximately $429,000.

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Mylan N.V. by 4.5% during the 2nd quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock valued at $1,575,089,000 after acquiring an additional 1,751,515 shares during the period. Vanguard Group Inc. boosted its holdings in Mylan N.V. by 12.0% during the 2nd quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after acquiring an additional 3,531,974 shares during the period. State Street Corp boosted its holdings in Mylan N.V. by 1.6% during the 2nd quarter. State Street Corp now owns 20,498,541 shares of the company’s stock valued at $795,751,000 after acquiring an additional 321,977 shares during the period. Pzena Investment Management LLC boosted its holdings in Mylan N.V. by 69.9% during the 2nd quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock valued at $479,027,000 after acquiring an additional 5,077,371 shares during the period. Finally, FIL Ltd lifted its holdings in Mylan N.V. by 1.9% in the 2nd quarter. FIL Ltd now owns 5,029,770 shares of the company’s stock worth $195,255,000 after buying an additional 95,505 shares during the period. Hedge funds and other institutional investors own 71.97% of the company’s stock.

Mylan N.V. (NASDAQ:MYL) traded up 0.05% on Wednesday, reaching $38.47. The company had a trading volume of 577,227 shares. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. The stock’s 50-day moving average is $32.53 and its 200-day moving average is $36.33. The company has a market capitalization of $20.63 billion, a P/E ratio of 31.10 and a beta of 1.30.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.16 earnings per share. Equities research analysts forecast that Mylan N.V. will post $4.58 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/11/moors-cabot-inc-invests-429000-in-mylan-n-v-myl.html.

Several equities research analysts have weighed in on the company. Cowen and Company reiterated a “hold” rating and issued a $30.00 price objective (down previously from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $32.00 price objective (down previously from $33.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Citigroup Inc. upgraded Mylan N.V. from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $36.00 to $42.00 in a report on Wednesday, August 16th. Wells Fargo & Company set a $32.00 price objective on Mylan N.V. and gave the stock a “hold” rating in a report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded Mylan N.V. from a “strong sell” rating to a “hold” rating and set a $43.00 price ob

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Mylan N.V. by 4.5% during the 2nd quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock valued at $1,575,089,000 after acquiring an additional 1,751,515 shares during the period. Vanguard Group Inc. boosted its holdings in Mylan N.V. by 12.0% during the 2nd quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after acquiring an additional 3,531,974 shares during the period. State Street Corp boosted its holdings in Mylan N.V. by 1.6% during the 2nd quarter. State Street Corp now owns 20,498,541 shares of the company’s stock valued at $795,751,000 after acquiring an additional 321,977 shares during the period. Pzena Investment Management LLC boosted its holdings in Mylan N.V. by 69.9% during the 2nd quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock valued at $479,027,000 after acquiring an additional 5,077,371 shares during the period. Finally, FIL Ltd lifted its holdings in Mylan N.V. by 1.9% in the 2nd quarter. FIL Ltd now owns 5,029,770 shares of the company’s stock worth $195,255,000 after buying an additional 95,505 shares during the period. Hedge funds and other institutional investors own 71.97% of the company’s stock.

Mylan N.V. (NASDAQ:MYL) traded up 0.05% on Wednesday, reaching $38.47. The company had a trading volume of 577,227 shares. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. The stock’s 50-day moving average is $32.53 and its 200-day moving average is $36.33. The company has a market capitalization of $20.63 billion, a P/E ratio of 31.10 and a beta of 1.30.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.16 earnings per share. Equities research analysts forecast that Mylan N.V. will post $4.58 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/11/moors-cabot-inc-invests-429000-in-mylan-n-v-myl.html.

Several equities research analysts have weighed in on the company. Cowen and Company reiterated a “hold” rating and issued a $30.00 price objective (down previously from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $32.00 price objective (down previously from $33.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Citigroup Inc. upgraded Mylan N.V. from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $36.00 to $42.00 in a report on Wednesday, August 16th. Wells Fargo & Company set a $32.00 price objective on Mylan N.V. and gave the stock a “hold” rating in a report on Wednesday, October 4th. Finally, Zacks Investment Research upgraded Mylan N.V. from a “strong sell” rating to a “hold” rating and set a $43.00 price objective for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.21.

Mylan N.V. Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply